TI
AKTX

Turner Investments’s Akari Therapeutics AKTX Stock Holding History

Turner Investments’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed -$13K – 182
2016
Q2 		$13K Buy
+1
New +$12.9K ﹤0.01% 198
2016
Q1 		– Sell
-40
Closed -$415K – 207
2015
Q4 		$468K Sell
40
-12
-23% -$178K 0.1% 187
2015
Q3 		$1M Buy
+52
New +$615K 0.2% 146

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Turner Investments's AKTX Position: Q3 2016 in Review

Turner Investments sold out of Akari Therapeutics (AKTX) in Q3 2016, closing a stake of 1 share — an estimated $13K sold.

Turner Investments first reported a position in AKTX in Q3 2015 and held it in 3 quarters. The position peaked at $1M in Q3 2015. 17 funds tracked by Wall St. Rank hold AKTX as of Q3 2016.

  • Turner Investments reported no remaining Akari Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Turner Investments sold 1 Akari Therapeutics share in Q3 2016, an estimated $13K.
  • Turner Investments first reported a position in Akari Therapeutics in Q3 2015 and held it in 3 quarters.
  • Turner Investments's Akari Therapeutics position peaked at $1M in Q3 2015.
  • 17 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2016.

Based on Turner Investments's 13F filing for Q3 2016, filed 14 Nov 2016.